Category Archives: BCMA

BMS, Gracell, CARsgen, and Fate Tx Report Clinical Results from Next-Generation Assets in MM; ASH 2022 Analysis 4

ASH 2022 Analysis 4: BMS, Gracell, CARsgen and Fate Tx presented clinical updates from their novel cell therapies in r/r MM. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered below:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

BMS and JNJ Report Clinical Updates from BCMA CAR-Ts in MM; ASH 2022 Analysis 2

ASH 2022 Analysis 2: BMS and JNJ presented updated results from their approved BCMA CAR-Ts in r/r MM. Below, Celltelligence provides insights and context for key selected presentations.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Fate Tx, Adicet Bio, and Allogene Report Clinical Updates from Allogeneic Cell Therapies; ASH 2022 Analysis 1

ASH 2022 Analysis 1: Fate Tx, Adicet Bio, and Allogene presented clinical updates from their allogeneic cell therapies in hematological malignancies. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered below:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Thoughts on Gilead’s Collaboration with Arcellx

On Friday, December 9, Gilead (Kite) and Arcellx announced (press release) a global strategic collaboration to co-develop and co-commercialize Arcellx’s CART-ddBCMA (autologous BCMA CAR-T) for the treatment of r/r MM. Additionally, Arcellx released (press release / presentation) clinical updates from CART-ddBCMA’s Ph1 trial in patients with r/r MM, ahead of its presentation at ASH 2022 (December 11; Abs#3313). Below, Celltelligence provides insights on Gilead’s strategic decision to enter the BCMA CAR-T space, while discussing potential FDA approval timelines for CART-ddBCMA and how it could compare with already approved BCMA CAR-Ts.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Allogene’s R&D Showcase 2022: Celltelligence Analysis – Part 1

On Tuesday, November 29, Allogene held an R&D showcase (press release / presentation) providing updated clinical milestones and results from ALLO-501A (allogeneic CD19 CAR-T) and ALLO-715 (allogeneic BCMA CAR-T). Below, Celltelligence provides insights on the new data presented by Allogene from its hematology franchise, while discussing potential regulatory timelines for ALLO-501A and how it could compete with approved autologous CAR-Ts.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

UPDATED: Indications Table for BCMA and CD19 CAR-T US Approvals and Submissions (Q3 2022)

New content: The Celltelligence team has updated its BCMA CAR-T and CD19 CAR-T indications tables for estimated US approvals and submissions following key Q3 2022 earnings presentations and recent press releases (see below for download). Another update will be published in December after ASH.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Gracell to Submit GC012F’s IND for R/R MM in the US and China; GC012F Demonstrates 100% ORR in NDMM; Clinical Progress from GC007g, GC503, and GC506; Gracell’s Q3 2022 Earnings Call Summary

On Monday, November 14, Gracell held their Q3 2022 earnings call (press release / presentation), highlighting results from GC012F’s (autologous BCMAxCD19 FasTCAR-T) Ph1/2 IIT in NDMM, and planned IND submissions in the US and China for r/r MM. Additionally, management provided clinical updates for GC007g (allogeneic CD19 CAR-T), GC503 (mesothelin SMART CAR-T), and GC506 (CLDN18.2 SMART CAR-T). Below, Celltelligence provides insights on GC012F’s potential as a first-line treatment in MM, while discussing a possible partnership strategy in the US.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

P-PSMA-101’s Clinical Enrollment Stopped; Multiple Program Updates Expected at ESMO I-O 2022; Poseida’s Q3 2022 Earnings Summary

On Thursday, November 10, Poseida released its Q3 2022 earnings results (press release) highlighting an enrollment halt in P-PSMA-101’s (autologous PSMA CAR-T) Ph1 study for metastatic castrate-resistant prostate cancer (mCRPC) and advanced salivary gland cancers (SGC). Additionally, clinical updates from P-MUC1C-ALLO1 (allogeneic MUC1-C CAR-T) and P-BCMA-ALLO1 (allogeneic BCMA CAR-T) are anticipated at ESMO Immuno-Oncology (I-O) 2022 (Dec 7 – 9). Below, Celltelligence provides insights on Poseida’s potential strategy in the PSMA programs, while discussing the anticipated data updates at ESMO I-O 2022.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

KarMMa-2 Results to be Presented at ASH 2022; No Updates for bbT369 and SC-DARIC33; PBCAR269A Discontinued; 2seventy bio and Precision BioSciences Q3 2022 Earnings Summaries

On Monday, November 7, 2seventy bio released their Q3 2022 earnings results (press release) highlighting Abecma’s (BMS / 2seventy’s BCMA CAR-T) increased revenue. Moreover, preliminary clinical results from Cohorts 2A and 2C of the Ph2 KarMMa-2 in ≥2L HR MM will be presented at ASH 2022 (Dec 10-13). On Tuesday, November 8, Precision BioSciences reported their Q3 2022 financials and business updates (press release) highlighting the discontinuation of PBCAR269A (allogeneic BCMA CAR-T). Below, Celltelligence provides insights on Abecma’s improved efficacy in the KarMMa-2 study, while discussing Precision’s decision to deprioritize its BCMA franchise.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Allogene Plans to Expand ALLO-501A’s Pivotal Trial to Europe; Clinical Updates Ahead of ASH 2022; New Manufacturing Facility in China; Allogene’s Q3 2022 Earnings Call Summary

On Wednesday, November 2, Allogene held its Q3 2022 earnings call (press release) highlighting the initiation of ALLO-501A’s (allogeneic CD19 CAR-T) Ph2 ALPHA2 trial in r/r LBCL and its potential expansion into the EU. Furthermore, management announced an R&D showcase on November 29, 2022, to provide updates on the ALLO-501A and ALLO-715 (allogeneic BCMA CAR-T) programs, while results from ALLO-715’s Ph1 UNIVERSAL study will also be presented at ASH 2022. Below, Celltelligence provides insights on Allogene’s potential involvement in ALLO-501A’s ex-US development, while discussing its allogeneic BCMA CAR-T strategy.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.